The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab

References

• Aarden, L., Ruuls, S. R., and Wolbink, G. 2008. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 20:431–435
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories, Limited. 2011. Product Monograph PrHumira. adalimumab, 40 mg in 0.8 ml sterile solution (50 mg/ml), subcutaneous injection. Abbott Laboratories, Quebec, Canada
   Google Scholar
• Baert, F., Noman, M., Vermeire, S., et al. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. New Engl. J. Med. 348:601–608
   PubMed Web of Science ®Google Scholar
• Baker, M. P., Reynolds, H. M., Lumicisi, B., and Bryson, C. J. 2010. Immunogenicity of protein therapeutics: Key causes, consequences and challenges. Self Nonself 1:314–322
   PubMedGoogle Scholar
• Bartelds, G. M., De Groot, E., Nurmohamed, M. T., et al. 2010. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther. 12:R221
   Google Scholar
• Bartelds, G. M., Krieckaert, C. L., Nurmohamed, M. T., et al. 2011. Development of anti-drug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305:1460–1468
   PubMed Web of Science ®Google Scholar
• Bartelds, G. M., Wijbrandts, C. A., Nurmohamed, M. T., et al. 2007. Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66:921–926
   PubMed Web of Science ®Google Scholar
• Bhogal, N. 2010. Immunotoxicity and immunogenicity of biopharmaceuticals: Design concepts and safety assessment. Curr. Drug Saf. 5:293–307
   PubMedGoogle Scholar
• Bode, G., Clausing, P., Gervais, F., et al. 2010. The utility of the minipig as an animal model in regulatory toxicology. J. Pharmacol. Toxicol. Meth. 62:196–220
   PubMed Web of Science ®Google Scholar
• Brinks, V., Jiskoot, W., and Schellekens, H. 2011. Immunogenicity of therapeutic proteins: The use of animal models. Pharm. Res. 28:2379–2385
   PubMed Web of Science ®Google Scholar
• Bugelski, P. J., and Treacy, G. 2004. Predictive power of pre-clinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Ther. 6:10–16
   PubMed Web of Science ®Google Scholar
• Büttel, I. C., Chamberlain, P., Chowers, Y., et al. 2011. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39:100–109
   PubMed Web of Science ®Google Scholar
• Chapman, K., Pullen, N., Coney, L., et al. 2009. Pre-clinical development of monoclonal antibodies: Considerations for the use of non-human primates. MAbs 1:505–516
   PubMed Web of Science ®Google Scholar
• Chapman, K., Pullen, N., Graham, M., and Ragan, I. 2007. Preclinical safety testing of monoclonal antibodies: Significance of species relevance. Nat. Rev. Drug Discov. 6:120–126
   PubMed Web of Science ®Google Scholar
• Chapman, K. L., Pullen, N., Andrews, L., and Ragan, I. 2010. The future of non-human primate use in mAb development. Drug Discov. Today 15:235–242
   PubMed Web of Science ®Google Scholar
• Descotes, J. 2009. Immunotoxicity of monoclonal antibodies. MAbs 1:104–111
   PubMed Web of Science ®Google Scholar
• Descotes, J., and Gouraud, A. 2008. Clinical immunotoxicity of therapeutic proteins. Expert. Opin. Drug Metab. Toxicol. 4:1537–1549
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2002. EMEA Public statement on Infliximab (Remicade), Update on safety concerns. EMEA, London, United Kingdom. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2010/08/WC500095471.pdf
   Google Scholar
• European Medicines Agency. 2004. Scientific discussion. EMEA, London, United Kingdom. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000481/WC500050867.pdf. 2004
   Google Scholar
• European Medicines Agency. 2006. Scientific Discussion. EMEA, London, United Kingdom. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000481/WC500050874.pdf
   Google Scholar
• European Medicines Agency. 2005. ICH Guidance for industry. S8 Immunotoxicity Studies for Human Pharmaceuticals EMEA, London, United Kingdom
   Google Scholar
• Food and Drug Administration. 1998. Infliximab Product Approval Information. USFDA, Silver Spring, United States of America. Available from: http://fda.gov
   Google Scholar
• Food and Drug Administration. 2002. Adalimumab Product Approval Information (1999-2002). USFDA, Silver Spring, United States of America. Available from: http://fda.gov
   Google Scholar
• Forster, R., Ancian, P., Fredholm, M., et al. 2010a. The minipig as a platform for new technologies in toxicology. J. Pharmacol. Toxicol. Meth. 62:227–235
   PubMed Web of Science ®Google Scholar
• Forster, R., Bode, G., Ellegaard, L., and van der Laan, J. W. 2010b. The RETHINK project--minipigs as models for the toxicity testing of new medicines and chemicals: An impact assessment. J. Pharmacol. Toxicol. Meth. 62:158–159
   PubMed Web of Science ®Google Scholar
• Hart, M. H., de Vrieze, H., Wouters, D., et al. 2011. Differential effect of drug interference in immunogenicity assays. J. Immunol. Meth. 372:196–203
   PubMed Web of Science ®Google Scholar
• Janssen Biotech, Inc. 2013. Full prescribing information. Janssen Biotech, Inc., Horsham, United States of America. Available from: http://www.remicade.com/hcp/prescribing-information
   Google Scholar
• Kromminga, A., and Schellekens, H. 2005. Antibodies against erythropoietin and other protein-based therapeutics: An overview. Ann. N.Y. Acad. Sci. 1050:257–265
   PubMed Web of Science ®Google Scholar
• Lobo, E. D., Hansen, R. J., and Balthasar, J. P. 2004. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93:2645–2668
   PubMed Web of Science ®Google Scholar
• Loyet, K. M., Deng, R. Liang, W. C., et al. 2009. Technology-comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J. Immunol. Meth. 345:17--28
   Google Scholar
• Paserchia, L. A. (FDA). Clinical Pharmacology Review of BLA 99-0128, Remicade (Supplement). USFDA, Silver Spring, United States of America. 1999. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107725.pdf
   Google Scholar
• Paserchia, L. A. (FDA). 1999. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107725.pdf
   Google Scholar
• Penninks, A. H., and van Mierlo, G. J. D. 2012. Immunotoxicity studies in minipigs. In: The Minipig in Biomedical Research (McAnulty, P. A., Dayan, A. D., Ganderup, N. C., and Hastings, K. L., Eds.). New York: CRC Press/Taylor and Francis, pp. 397–411
   Google Scholar
• Ponce, R., Abad, L., Amaravadi, L., et al. 2009. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 54:164–182
   PubMed Web of Science ®Google Scholar
• Ryffel, B. 1997. Safety of human recombinant proteins. Biomed. Environ. Sci. 10:65–72
   PubMedGoogle Scholar
• Sauerborn, M., Brinks, V., Jiskoot, W., and Schellekens, H. 2010. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol. Sci. 31:53–59
   PubMed Web of Science ®Google Scholar
• van de Putte, L. B., Atkins, C., Malaise, M., et al. 2004. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying anti-rheumatic drug treatment has failed. Ann. Rheum. Dis. 63:508–516
   PubMed Web of Science ®Google Scholar
• van der Laan, J. W., Brightwell, J., McAnulty, P., et al. 2010. Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals, and other products. J. Pharmacol. Toxicol. Meth. 62:184–195
   PubMed Web of Science ®Google Scholar
• van Mierlo, G. J. D., Cnubben, N. H. P., Kuper, C. F., et al. 2013. The Göttingen minipig as an alternative non-rodent species for immunogenicity testing: A demonstrator study using the IL-1 receptor antagonist anakinra. J. Immunotoxicol. 10:96–105
   PubMed Web of Science ®Google Scholar
• van Schouwenburg, P. A., Bartelds, G. M., Hart, M. H., et al. 2010. A novel method for the detection of antibodies to adalimumab in presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J. Immunol. Meth. 362:82–88
   PubMed Web of Science ®Google Scholar
• Wierda, D., Smith, H. W., and Zwickl, C. M. 2001. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 158:71–74
   PubMed Web of Science ®Google Scholar
• Wolbink, G. J., Vis, M., Lems, W., et al. 2006. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54:711–715
   PubMed Web of Science ®Google Scholar